Li Zhang, Master
Sun Yat-Sen University Cancer Center · Sun Yat-sen University · West China Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Li Zhang, Master as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:13 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07010419 · A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）Allist Pharmaceuticals, Inc. · recruiting · NSCLC, Adjuvant Treatment · principal investigator
- Ph2NCT06514027 · Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion MutationsBeBetter Med Inc · recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph1NCT06032936 · BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR MutationsLianBio LLC · terminated · NSCLC · principal investigator
- Ph1NCT05621525 · Phase I Study of the BBP-398 in Patients With Advance Solid TumorsLianBio LLC · terminated · Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer · principal investigator
- N/ANCT05487066 · Efficacy of ICU-VTE Scale in ICU PatientsLijuan Zhang · completed · Venous Thromboembolism · principal investigator
- Ph4NCT05329038 · Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 VaccineSinovac Life Sciences Co., Ltd. · unknown · COVID-19 · principal investigator
- Ph4NCT04953325 · Immunogenicity and Safety of an Inactivated COVID-19 VaccineSinovac Research and Development Co., Ltd. · completed · COVID-19 · principal investigator
- Ph2NCT04164745 · Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerPeking Union Medical College Hospital · unknown · NSCLC · principal investigator
- Ph1NCT01226030 · Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid TumorsBeijing Protgen Biotechnology Development Co., Ltd. · unknown · Advanced Solid Tumors · principal investigator
- Ph2NCT00697619 · To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal CancerSun Yat-sen University · completed · Nasopharyngeal Cancer · principal investigator
- Ph2NCT00630149 · Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based ChemotherapySun Yat-sen University · completed · Nasopharyngeal Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.